Becca Stanek is an experienced writer and editor who is passionate about exploring the ways we can feel better mentally and physically to get the most out of our lives. She has worked for publications ...

To address the nationwide shortage of medications for attention-deficit/hyperactivity disorder, the Drug Enforcement Administration is allowing an increase in the ...

Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States. The U.S. Food and ...

The maker of the ADHD drug Vyvanse has been given approval by the US Drug Enforcement Administration to make more of the medication as a shortage of the critical drugs continues. HealthDay News — The ...

In a significant move to mitigate the ongoing shortage of ADHD medications in the U.S., the Drug Enforcement Administration (DEA) has authorized a substantial increase in the production limits for ...

Takeda says the situation affects its 40-mg, 60-mg and 70-mg dosage strengths of Vyvanse. The 40-mg dose supply "will dip in mid-June and will be replenished in a few weeks," according to Takeda's ...

LONDON (Reuters) - Shire has struck a deal with GlaxoSmithKline, the world's second largest drugs group, to co-promote its hyperactivity medicine Vyvanse in the United States, sending its shares ...

WASHINGTON — The Drug Enforcement Administration has increased the production limit for the ADHD drug Vyvanse and its generic versions to combat the medicine's ongoing shortage, according to a notice ...

Add Yahoo as a preferred source to see more of our stories on Google. Supply from drugmakers for the stimulant medications most commonly prescribed for ADHD are still falling short of demand, the Food ...